Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA1D | P25100 | 4/20 | 0.71 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.65 |
| ▸ | HTR2A | P28223 | 1/20 | 0.62 |
| ▸ | HTR7 | P34969 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL7259035 | 0.99 | ADRA1D (0.71) | ADRA1DSLC6A4HTR2AHTR7 | |
| SCHEMBL5730515 | 0.98 | ADRA1D (0.69) | ADRA1DSLC6A4HTR2AHTR7 | |
| Hydrochloric Acid SCHEMBL7261121 | 0.97 | ADRA1D (0.70) | ADRA1DSLC6A4HTR2AHTR7 | |
| SCHEMBL7260935 | 0.97 | ADRA1D (0.71) | ADRA1DSLC6A4HTR2AHTR7 | |
| Hydrochloric Acid SCHEMBL7259962 | 0.96 | ADRA1D (0.72) | ADRA1DSLC6A4HTR2AHTR7 | |
| Hydrochloric Acid SCHEMBL7256791 | 0.96 | ADRA1D (0.72) | ADRA1DSLC6A4HTR2AHTR7 | |
| SCHEMBL9671736 | 0.93 | HTR7 (0.67) | ADRA1DSLC6A4HTR2AHTR7 | |
| Hydrochloric Acid SCHEMBL7261098 | 0.92 | HTR7 (0.66) | ADRA1DSLC6A4HTR2AHTR7 | |
| Hydrochloric Acid SCHEMBL7259157 | 0.87 | ADRA1D (0.90) | ADRA1DSLC6A4 | |
| SCHEMBL7260967 | 0.85 | ADRA1D (0.67) | ADRA1DSLC6A4HTR2AHTR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050245540-A1 | New methods | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2005-11-03 | — | — | US | disclosed |
| US-6642228-B1 | Treating ocular tension, carcinoma, sarcoma, tumentia, circulatory disease, or hypertension | TORAY INDUSTRIES, INC. (JP) | 2003-11-04 | — | — | US | disclosed |
| EP-1106605-A1 | ALPHA1B-ADRENERGIC RECEPTOR ANTAGONISTS | TORAY INDUSTRIES, INC. (JP) | 2001-06-13 | — | — | EP | disclosed |
| EP-0324431-B1 | NEW INDOLYLPIPERIDINE COMPOUNDS, PROCESSES FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1992-03-25 | — | — | EP | disclosed |
| US-5017703-A | Antiallergens, antiinflammatory | FUJISAWA PHARMACEUTICAL COMPANY, LTD. (JP) | 1991-05-21 | — | — | US | disclosed |
| US-4935432-A | ANTIALLERGENS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1990-06-19 | — | — | US | disclosed |
| EP-0324431-A1 | New indolylpiperidine compounds, processes for the preparation thereof and pharmaceutical composition comprising the same | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1989-07-19 | — | — | EP | disclosed |
| US-3950527-A | SEDATIVES | ROUSSEL-UCLAF (FR) | 1976-04-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050245540-A1 | New methods | TGFB1, TGFBR1, TGFB2 | ADRA1D 95/4885SLC6A4 1968/4885HTR2A 1054/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.